This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
7/22/2026
Operator
Conference Operator
Good day and welcome to the Hansa Biopharma second quarter and first half year 2026 financial results conference call. All participants will be in listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renée Aguirre-Lucander. Please go ahead.
Renée Aguirre-Lucander
Chief Executive Officer
Thank you very much. Good afternoon and good morning, everybody. Welcome to the Hansa Biopharma Conference call to review the Q2 results for 2026. I'm Renée Aguirre-Lucander, CEO for Hansa Biopharma. Joining me today is Adam Cutler, Chief Financial Officer, Richard Philipson, Chief Medical Officer, and Maria Tarnson, Chief Operating Officer and President of the US. Please turn to the next page. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during the presentation, and you should therefore apply appropriate caution. Next slide, please.
Maria Tarnson
Chief Operating Officer and President, US
This is the brief agenda for today's call.
You're reading a preview of the HNSA.ST Q2 2026 earnings call.
Free account.
Disclaimer